Impact of Methionine Synthase Reductase Polymorphisms in Chronic Myeloid Leukemia Patients.
Abozer Y Elderdery, Entesar M Tebein, Fawaz O Alenazy, Ahmed M E Elkhalifa, Manar G Shalabi, Anass M Abbas, Hassan H Alhassan, Chand B Davuljigari, Jeremy Mills
Author Information
Abozer Y Elderdery: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka 72388, Saudi Arabia. ORCID
Entesar M Tebein: College of Applied Medical Sciences, Shaqra University, Shaqra 11961, Saudi Arabia. ORCID
Fawaz O Alenazy: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka 72388, Saudi Arabia. ORCID
Ahmed M E Elkhalifa: Department of Public Health, College of Health Sciences, Saudi Electronic University, Riyadh 11673, Saudi Arabia. ORCID
Manar G Shalabi: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka 72388, Saudi Arabia.
Anass M Abbas: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka 72388, Saudi Arabia. ORCID
Hassan H Alhassan: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka 72388, Saudi Arabia.
Chand B Davuljigari: Department of Zoology, College of Sciences, Sri Venkateswara University, Tirupati 517502, Andhra Pradesh, India.
Jeremy Mills: School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth PO1 2UP, UK. ORCID
Introduction： Metabolism methionine and of folate play a vital function in cellular methylation reactions, DNA synthesis and epigenetic process.However, polymorphisms of methionine have received much attention in recent medical genetics research. Objectives: To ascertain whether the common polymorphisms of the MTRR (Methionine Synthase Reductase) A66G gene could play a role in affecting susceptibility to Chronic Myeloid Leukemia (CML) in Sudanese individuals. Methods: In a case-controlled study, we extracted and analyzed DNA from 200 CML patients and 100 healthy control subjects by the PCR-RFLP method. Results: We found no significant difference in age orgender between the patient group and controls. The MTRR A66G genotypes were distributed based on the Hardy-Weinberg equilibrium (p > 0.05). The variation of MTRR A66G was less significantly frequent in cases with CML (68.35%) than in controls (87%) (OR = 0.146, 95% CI = 0.162−0.662, p < 0.002). Additionally, AG and GG genotypes and G allele were reducing the CML risk (Odds ratio [OR] = 0.365; 95% CI [0.179−0.746]; p = 0.006; OR = 0.292; 95% CI [0.145−0.590]; p = 0.001 and OR = 0.146; 95% CI [0.162−0.662]; p = 0.002 and OR = 2.0; 95% CI [1.3853−2.817]; respectively, (p = 0.000)). Conclusions: Our data demonstrated that heterozygous and homozygous mutant genotypes of MTRR polymorphisms were associated with decreased risk of developing CML in the Sudanese population.
